June 27, 2025 – Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity

June 25, 2025 – Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects

June 20, 2025 – PRESENTATION – Randomized Phase 1a Single-Ascending Dose Study of ENT-03 in Healthy Obese Subjects and Subjects with Type 2 Diabetes

June 20, 2025 – ABSTRACT – Randomized Phase 1a Single-Ascending Dose Study of ENT-03 in Healthy Obese Subjects and Subjects with Type 2 Diabetes